Netherlands testing 'no cure, no pay' model for cancer drugs: 4 things to know

The Netherlands is testing a "no cure, no pay" reimbursement model for expensive cancer drugs, according to Medscape.

Four things to know:

1. Under the payment model, certain expensive cancer drugs will only be reimbursed if they are effective after a 16-week period. 

2. The payment model pilot program was designed by Dutch oncologists, researchers at the Netherlands Care Institute and health insurers. It is supported by Bristol-Myers Squibb.

3. Under the pilot program, 135 patients with rare MSI-H tumors will receive the immunotherapy nivolumab, paid for by Bristol-Myers, for 16 weeks. For every patient with tumor shrinkage or no disease progression, the drugmaker will be able to claim reimbursement. The drugmaker won't be reimbursed for patients who do not respond to the treatment. 

4. The country hopes that the model will give patients better access to expensive medications.

Access the full report here

More articles on pharmacy:
Judge blocks HHS rule requiring drug prices in TV ads
Nation's 1st prescription drug affordability board goes into effect
11 healthcare pharma leaders offer advice on controlling drug spend

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months